从低血糖风险深入探讨如何选择胰岛素  

To Explore the Choice of Insulin from the Risk of Hypoglycemia

作　　者：沈建国[1] SHEN Jianguo(The First Affiliated Hospital,Zhejiang University,Hangzhou Zhejiang 310003,China)

机构地区：[1]浙江大学医学院附属第一医院,浙江杭州310003

出　　处：《药品评价》2021年第22期1345-1349,共5页Drug Evaluation

摘　　要：低血糖是糖尿病患者降糖治疗中不可忽视的问题,可进一步导致多种严重的临床不良预后,反过来影响血糖控制。低血糖的诊断标准一直以来存在争议,统一低血糖的诊断标准有利于开展临床研究以评估新药物、新技术的安全性。该研究从低血糖的病理生理变化,诊断界值、危害、降低多少低血糖风险才具有临床意义等方面来探讨哪类基础胰岛素类似物在减少低血糖方面更具优势;指出长效胰岛素类似物能更好地模拟生理基础胰岛素作用,具有低血糖风险小的优势,其中,德谷胰岛素相较于甘精胰岛素U100和U300,低血糖风险更小。Hypoglycemia is a vital side effect of medical therapy in diabetic patients,which further lead to a series of critical adverse events,restricting the development of hypoglycemic therapy in turn.The diagnostic criteria of hypoglycemia have been controversial for a long time,and making a consensus on diagnostic criteria of hypoglycemia may contribute to conducting clinical trials assess the safety of new drugs and technologies for diabetic patients.The study mainly introduces the diagnosis and harm of hypoglycemia,as well as the benefits of lowering hypoglycemia risk,and explore which basic insulin analogues have more advantages in reducing hypoglycemia.The long-acting insulin analogs can better mimic physiological basal insulin action and have the advantage of a small risk of hypoglycemia,where insulin degludec has a lower risk of hypoglycemia compared to insulin glargine U100 and U300.

关 键 词：降血糖药 药物相关性副作用和不良反应 糖尿病 2型 低血糖 基础胰岛素 德谷胰岛素 

分 类 号：R587.1[医药卫生—内分泌]